Clinical Trial Update: Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on chidamide plus golidocitinib for relapsed/refractory peripheral T-cell lymphoma, spanning Phase 1 and Phase 2; currently not yet recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Golidocitinib (golidocitinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Peripheral T-cell Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING